RxDoctor Payments Data

James Adams, MD

Family Medicine · Palm Springs, CANPI 1184681439

Payments from drug & device makers

$14,886in general payments, 2019–2025

Across 106 payments — averaging $140.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$7K
  • Gilead$4K
  • Theratechnologies Inc.$3K
  • Merck$446
  • Janssen Scientific Affairs, LLC$218
  • Amgen$168
  • plus $859 from 11 others

What the payments were for

  • Consulting fees$9,75065%
  • Speaking & faculty fees$160%
  • Travel & lodging$4173%
  • Food & beverage$4,70332%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,886 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$30,009
Medicare patients
74
Services billed
281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala138$642,715
OzempicSemaglutide116$144,440
DovatoDolutegravir Sodium/Lamivudine33$99,262
PrezcobixDarunavir/Cobicistat37$92,391
CabenuvaCabotegravir/Rilpivirine13$85,101
DescovyEmtricitabine/Tenofov Alafenam26$74,611
JulucaDolutegravir/Rilpivirine19$72,100
JardianceEmpagliflozin43$57,664
EliquisApixaban38$51,718
TriumeqAbacavir/Dolutegravir/Lamivudi12$43,744
IsentressRaltegravir Potassium13$39,583
Maraviroc23$29,633
JanuviaSitagliptin Phosphate14$24,228
Darunavir14$22,185
RybelsusSemaglutide14$19,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$3,657$717,326164 claims
Viiv Healthcare CompanyDovato, Cabenuva, Juluca, Triumeq$6,906$300,20777 claims
Novo NordiskOzempic, Rybelsus$87$163,596130 claims
Johnson & JohnsonPrezcobix$76$92,39137 claims
MerckIsentress, Januvia$446$63,81127 claims
Boehringer IngelheimJardiance$62$57,66443 claims
PfizerEliquis, Paxlovid$51$55,88358 claims
AbbVieSynthroid$146$93632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Palm Springs

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →